Answers are grounded in this paper and cite their sources.
OBJECTIVES: The idiopathic inflammatory myopathies (IIMs) form a rare, heterogeneous group of autoimmune diseases characterised by weakness and inflammation of skeletal muscle. Autoantibody titre holds potential as a novel biomarker for monitoring disease activity and treatment response in IIM. In this study, the association between anti-Jo1, anti-Ro52 (TRIM21) and anti-TIF1γ titres and clinical measurements of disease activity was assessed in cross-sectional and longitudinal patient samples from the MYOPROSP cohort. METHODS: MYOPROSP was a multi-centre prospective cohort study of adult UK IIM patients that ran from 2016-2020. Enzyme-linked immunosorbent assays (ELISAs) were used to quantify autoantibody titres in MYOPROSP plasma samples. Associations between longitudinal titres and clinical measurements of IIM disease activity were assessed using linear mixed models. RESULTS: Cross-sectional analysis did not show a significant association between titres of anti-Jo1, anti-Ro52 or anti-TIF1γ and measures of IIM clinical disease activity at baseline. However, longitudinal analysis demonstrated that changes in anti-Jo1 titre (n = 36) correlated positively with changes in Physician Global Activity (Estimate=0.161, p = 0.008) and Extramuscular Disease Activity (Estimate=0.168, p = 0.002), and negatively with changes in Total Improvement Score (Estimate=-0.238, p < 0.001) in IIM patients. Changes in anti-Ro52 (n = 19) and anti-TIF1γ titre (n = 9) was not significantly correlated with changes in clinical measurements. CONCLUSION: Longitudinal changes in anti-Jo1 titre reflected disease activity and improvement in IIM, whereas cross-sectional analysis suggested that differences in autoantibody titres between individuals were not associated with differences in disease activity at baseline.
No takes yet. Share an insight, caveat, or question.
Tomlinson et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: